Search PubMed⌕ Search

Biomedical subjects

J Markowska

Publications and source records attributed to J Markowska.

At least 37 records · Page 2Linked to original sources
PubMed1998

Significance of tissue polypeptide specific antigen (TPS) in diagnosis and monitoring of treatment in ovarian cancer.

Tissue polypeptide specific antigen (TPS) finds increasingly broad application in diagnosis and monitoring of treatment in ovarian cancer. Its sensitivity increases in parallel to clinical advancement of the tumor and to the grade of cellular differentiation. TPS may represent valuable supplementation of conventional markers in diagnosis of mucous carcinoma. Improved sensitivity and specificity of the technique for detection of ovarian cancer occur when two or more additional tumour markers are used in parallel. TPS has been found to represent a dependable index of surgical completeness. Determination of TPS in the sera of patients with ovarian cancer in the course of chemical treatment provides important information on the course of the neoplastic process and defines the response of the host to the applied treatment.

Biomarkers, Tumor↗
PubMed1997

Bleomycin-induced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay.

The studies concerned the response to bleomycin treatment in peripheral blood lymphocytes (PBL) of breast cancer (BC) subjects. The level of BLM-induced DNA strand breaks was evaluated using alkaline comet assay followed by visual scoring. The sensitivity to genotoxic exposure as well as the time-course of damage removal were estimated and analysed in comparison to control (healthy) subjects. Despite high inter-individual variability, the differences between the BC and non-cancer groups still proved to be statistically significant. Lymphocytes of the BC subjects appeared to be more sensitive to BLM exposure as shown by higher level of DNA damage. The DNA repair capacity was weaker in PBL obtained from BC patients than that in lymphocytes of controls.

Adult↗
PubMed1997

[Steps in the treatment of ovarian cancer].

The paclitaxel/cisplatin regimen is superior to standard therapy PC based on higher overall response rates, higher negative second-look laparotomy rate and overall survival. The regimen paclitaxel/cisplatin/cyclophosphamide seem to give the best treatment results. Interval debulking surgery after initial laparotomy and intraperitoneal therapy with cisplatin and i.v. cyclophosphamide in patients with residual disease improve overall survival rate.

Adult↗
PubMed1996

[Role of second-look surgery in treatment of ovarian neoplasms].

The operation second-look was carried out on 66 women with ovarian cancer without any clinical symptoms of disease. 14 of them (21.2%) showed persistent cancer, including 5-cancer in early stages. The level of CA 125 didn't exceed 35 U/ml in 60 women, and in 5 women persistent cancer wasn't detected during the second-look operation. Negative result of second-look operation doesn't inform about recovery because in 8 women out of 52 recurrence of cancer reported.

Adult↗
PubMed1996

Relation between infection with human papilloma viruses and expression of p21 and p53 oncoproteins in patients with cancer of the uterine cervix.

Infection with HPV type 16 was demonstrated in 54% of the cases and infection with HPV type 18 in 36.5% of the cases of uterine cervix carcinoma. Both types of viruses were present in 24.3% of the patients. P53 protein accumulation in cell nuclei was observed in 12.2% of the cases of uterine cervix carcinomas and the cases were mostly HPV negative while the cytoplasmic expression of p53 protein was present in 39% of the cases and was frequently accompanied by HPV infection. Presence of p21 protein was detected in 85.3% of the cases, independently of HPV infection or expression of p53 protein.

Female↗
PubMed1996

Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix.

The analyzed material included 41 sections originating from patients with squamous cell carcinoma at the III stage of clinical advancement. Size of tumor growth fractions and expression of p53 were evaluated using immunohistochemical methods. In most of cases, the Ki 67 index for uterine cervix carcinoma at the III stage of clinical advancement ranged between 5 and 30%. The p53 protein could seldom be detected, indicating infrequent p53 mutations in uterine cervix carcinoma. In cases exhibiting nuclear accumulation of p53 the proliferative index was high and ranged between 50% and 80%.

Antibodies, Monoclonal↗
PubMed1996

[The value of CA 125 levels in serum, peritoneal fluid and tumor in women with ovarian cancer].

The patients group consisted of 133 women with primary ovarian carcinoma at the average age of 56. According to the size of tumor diagnosed preoperatively, patients were divided into 3 groups: with tumor smaller than 5 cm, with tumor between 5 and 10 cm and over 10 cm. 74 women were tested for antigen CA 125 in the serum preoperatively and all of them were tested for it postoperatively. Moreover 28 samples of the antigen were tested in the peritoneal fluid and 7 samples in the tumor tissue. The tests on correlation of CA 125 level and the tumor size, process of cancer disease and histopathological type of cancer were carried out. Our data show that the reduction of tumor mass decreases marker level in the serum. Not in all cases of progression and recurrence the increased level of CA 125 was observed. There is, however, correlation between increased CA 125 level and histopathological type of cancer--the highest for serous and undifferentiated cancers. The marker level is the highest in the tumor and decreases in the peritoneal fluid and serum which proves that the marker is produced by tumor cells.

Adult↗
PubMed1996

[Chondrosarcoma of the small pelvis imitating an ovarian tumor].

The authors present diagnostic-therapeutic record concerning chondrosarcoma-tumor in 41-year-old women operated on ovary-tumor. They point out the rareness of chondrosarcoma within pelvis, the diagnostic and therapeutic difficulties and relapses into illness after radical remove of tumour without pelvis bones resection.

Adult↗
PubMed1995

The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients.

Twenty-seven ovarian cancer patients were observed for twenty-four months. The patients were grouped as follows: Group I-with complete (CR) or partial remission (PR), Group II-with stable disease (SD), Group III-with progression (PD) of the disease. In all patients, T lymphocyte phenotypes were estimated in peritoneal fluid (PF) and in peripheral blood (PB). No differences were observed in either PF and PBT (CD3+) cell percentages among the examined groups of patients. A slight increase was noted in the percentage of CD4+ cells upon transition from the remission group to the groups with less favourable outcome of treatment. The increase was observed both in PB and in PF but only the latter showed statistically significant changes. On the contrary, percentage of T-cytotoxic/suppressor (CD8+) lymphocytes decreased upon transition from patients with the remission to those with stable disease and those with progression. These changes strongly affected the CD4/CD8 ratio. In PF, CD4/CD8 ratios were 2.13 +/- 0.9 and 4.18 +/- 1.6 in Group II and III, respectively (p < 0.01). In PB, the ratios were 1.88 +/- 1.1, 1.75 +/- 0.6, and 4.32 +/- 1.5 in Groups I, II and III respectively (Group I vs. Group III p < 0.01, Group II vs. Group III p < 0.01). During the study, five patients died due to ovarian cancer. In retrospective analysis, these patients showed progressive increase in CD4/CD8 ratio of PFT cells. Just before death, the ratio demonstrated an abrupt increase. In conclusion, the estimation of CD4+ and CD8+ cells as well as calculation of CD4/CD8 ratio for lymphocytes of peripheral blood and peritoneal fluid seems helpful in monitoring disease progression in ovarian cancer patients.

Adenocarcinoma↗
PubMed1995

Expression of p53 and coexistence of HPV in premalignant lesions and in cervical cancer.

Fifty-four paraffin embedded tissue sections from patients with dysplasia (21 cases) and with cervical cancer (33 cases) were analysed. HPV was detected and identified in two stages. Firstly, using mixed starters, chosen genomic DNA sequences were amplified; secondly the material thus obtained was analyzed by hybridization method using oligonucleotyde 31-P labelled probe. HPVs of type 6, 11, 16, 18, 33 were identified. The p-53 expression was assayed by immunohistochemical method. HPV infection was often associated with dysplasia and cervical cancer. In cervical cancer mainly HPV 16 and 18 with high oncogenic potential were found. The p-53 was present rarely, and in minute quantities. No correlation was observed between presence of p-53 and HPVs DNA.

DNA Probes, HPV↗
PubMed1994

[Two cases of cancer developing from endometriosis in the minor pelvis 5 and 2.5 years after hysterectomy and adnexectomy].

In two cases, 5 and 2.5 years after hysterectomy and bilateral adnexectomy (myomata uteri, bilateral endometrioid cysts and pelvic endometriosis) endometrioid carcinoma developed. Finding out the endometriosis during operation is an indication for precise removing of its residual and following careful examinations over the period of many years.

Carcinoma, Endometrioid↗
PubMed1994

The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer.

CA 125 levels were estimated by immunoenzymatic technique: in fluids obtained by puncturing benign ovarian cysts under guidance of USG and in the patients' sera (23 cases); in serum and in ascites of 39 ovarian cancer patients at the IIIrd or IV th stage of clinical advance; in the content of malignant tumors in the course of surgery (in 16 of the above listed patients). Ca 125 level was significantly lower in the content of benign Cysts as compared to malignant ones. CA 125 level higher than 1000/ml pointed to a malignant process. Both in serum and in ascites, more advanced tumors and tumors showing progression manifested higher levels of the marker than less advanced tumors and tumors characterized as stable disease. In the group of patients analysis of CA 125 levels provided less information on the disease course than in individual cases.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1994

Results of topical treatment of HPV infection in the uterine cervix using interferon beta, 13-cis-retinoic acid and TFX.

Local treatment was administrated to 130 women, in whom colposcopy, cytology and (if the latter was abnormal) histology pointed to HPV infection in uterine cervix. The best results were obtained with 13-cis-retinoic acid (provitamin A) in conjunction with interferon beta (94.2% cured patients), followed by interferon beta in combination with TFX (90% cured patients) and interferon beta administered alone (88% cured patients).

Administration, Topical↗
PubMed1993

[Side effects of drug treatment for ovarian cancer after administration of antiemetic drugs].

The occurring frequency of 14 most common chemotherapy and anti-nausea drug side-effects was examined. The studies were performed on 29 women with ovarian cancer treated by total number of 125 chemotherapy courses (schedule PAC and Acy) and additionally, in order to eliminate nausea caused by the chemotherapy, by anti-nausea drugs (Zofran, Solu-Medrol, Droperidol, Metoclopramide + Fenactil, Torecan). Zofran caused the fewest number of side-effects, solu-medrol inhibited nausea and vomiting significantly, however it caused many side-effects such as flush on a face, restlessness, incitement and headaches. Torecan did not prevent patients from vomiting. The greatest number of side-effects was observed after droperidol and metoclopramide + fenactil treatment.

Adult↗
PubMed1993

[Survival, complications and quality of life in patients with breast cancer after ovariectomy and hormonal therapy].

Seventy one women with breast cancer in clinical stage IIIa were treated by chemotherapy and radical operation on the basis five features, namely: survivals, relapses, metastases, quality of life, and post-therapy complications. The two treatment methods were compared. The dependence between survivals and time elapsed between breast surgery and ovariectomy was evaluated. Women treated by ovariectomy suffer from; menopause symptoms, osteoporosis, blood coagulation distortions more after than women treated by hormonotherapy. Tamoxifen therapy increases the rate of breast cancer relapses and probably it is the cause of breast cancer metastases into liver. Women who underwent hormonal castration are professionally active more after them women treated by ovariectomy. Time elapsed between breast surgery and ovariectomy does not affect survivals in stage IIIa. In stage IIIb however, performing later ovariectomy prolongs survivals.

Adult↗